TransMedics (TMDX) is a buy for 2028, with strong revenue growth, improved margins, and limited dilution. Read here for more analysis.
As featured in ELLE’s best songs of April 2025: “Moody and bass-y, the verses of The Marías’ latest single creep in with lead ...
XHB outperforms ITB in short to medium-term returns and risk-adjusted metrics, benefiting from a broad recovery thesis. Read ...
As featured in ELLE’s best songs of April 2025: “Moody and bass-y, the verses of The Marías’ latest single creep in with lead ...
Farran Powell is the managing editor of investing at Forbes Advisor. She was previously the assistant managing editor of investing at U.S. News & World Report. Her work has appeared in numerous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback